Virdante said it's raised $48m since early 2008
October 29, 2009 09:21 AM
E-mail|
|Comments
()|
Text size
–
+
Virdante Pharmaceuticals, a Cambridge company developing drugs for autoimmune and inflammatory diseases, said that new funding it has received brings the amount of Series A funding it began raising in January 2008 to $47.75 million.
In a press release, Virdante said its investors include Clarus Ventures; Venrock; Thomas, McNerney & Partners; MedImmune Ventures; Biogen Idec New Ventures; and Osage Partners.
Virdante said it is seeking to incorporate a proprietary "Sialic Switch" technology to improve the anti-inflammatory properties of antibodies. (Globe Staff)
Comment
Permalink
E-mail
